“Treating metabolic disease progression, rather than symptoms”
It is undeniable that current medicines can adequately manage blood glucose in the short-term.
However, there is growing frustration among metabolic disease sufferers and healthcare professionals regarding the inability of currently available antidiabetic medications to slow or prevent the progressive loss of insulin-producing beta-cells in type 2 diabetes.
DBL are aiming to address this through development of our therapeutic pipeline.
In scientific rigour
In tackling unprecedented targets
Working with transparency and integrity
Valuing diversity in the workplace
Closely to our partners and investors
Embedded at the heart of innovation in Northern Ireland